Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis
- 14 February 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 66 (3) , 436-438
- https://doi.org/10.1212/01.wnl.0000195887.63124.dc
Abstract
Thirty-six patients with subarachnoid and intraventricular cysticercosis were randomly assigned to receive albendazole at 15 or 30 mg/kg/day plus dexamethasone for 8 days. Results favored a higher dose, with larger cyst reduction on MRI at 90 and 180 days and higher albendazole sulfoxide levels in plasma. An albendazole course at 30 mg/kg/day combined with corticosteroids is safe and more effective than the usual dose. A single treatment was insufficient in intraventricular and giant cysts.Keywords
This publication has 9 references indexed in Scilit:
- Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosisJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Current Consensus Guidelines for Treatment of NeurocysticercosisClinical Microbiology Reviews, 2002
- Medical Treatment for Neurocysticercosis Characterized by Giant Subarachnoid CystsNew England Journal of Medicine, 2001
- Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricleJournal of Neurosurgery, 1997
- Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Albendazole therapy for neurocysticercosisNeurology, 1997
- Neurocysticercosis: Focus on Intraventricular DiseaseClinical Infectious Diseases, 1997
- Large Cerebral Infarction During Praziquantel Therapy in NeurocysticercosisStroke, 1997
- Sensitive high-performance liquid chromatographic assay for albendazole and its main metabolite albendazole sulphoxide in plasma and cerebrospinal fluidJournal of Chromatography B: Biomedical Sciences and Applications, 1989